ValoTx Appoints Marcella Origgi as CEO to Accelerate Immuno-Oncology Growth

Valo Therapeutics has announced the appointment of Marcella Origgi as its new Chief Executive Officer, marking a significant milestone in the company’s growth trajectory. Marcella brings a wealth of experience from her time at Johnson & Johnson Innovation, where she led strategic initiatives in oncology, immunology, and advanced therapies. Based in Italy, she will oversee operations at both the Helsinki headquarters and the Naples subsidiary. Her leadership comes at a critical time, as ValoTx prepares to advance its promising PeptiCRAd-1 candidate through a Phase 1B trial across Germany, Italy, and Australia, fueled by a recent €19 million funding round.

Marcella’s deep background in immunology, medical strategy, and external innovation makes her a compelling fit to drive ValoTx's mission forward. Her previous roles at Janssen involved hands-on leadership in medical affairs and clinical strategy for multiple immunotherapies. Now at the helm of ValoTx, she’s poised to guide the company’s vision of creating adaptable cancer treatments into its next chapter—bringing innovative immunotherapies closer to patients who need them most.